Published in PLoS One on May 12, 2016
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) | NCT00027352
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis (2016) 0.82
Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217. J Acquir Immune Defic Syndr (2017) 0.75
Immunosenescence and hurdles in the clinical management of older HIV-patients. Virulence (2017) 0.75
Inflammation Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? J Acquir Immune Defic Syndr (2017) 0.75
MicroRNAs: novel tools to block gut inflammation in HIV? AIDS (2017) 0.75
Elevated ischemic stroke risk among women living with HIV infection. AIDS (2017) 0.75
Coronary artery endothelial dysfunction is present in HIV positive individuals without significant coronary artery disease. AIDS (2017) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
The coagulopathy of chronic liver disease. N Engl J Med (2011) 5.63
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol (1996) 3.82
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis (2010) 3.79
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr (2009) 2.99
Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol (2009) 2.61
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost (2009) 2.08
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol (2003) 1.99
Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation (2005) 1.89
Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol (1999) 1.73
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology (2011) 1.59
Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis (2008) 1.56
Adjustment for regression dilution in epidemiological regression analyses. Ann Epidemiol (1998) 1.43
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS (2013) 1.34
Regression dilution in the proportional hazards model. Biometrics (1993) 1.29
Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol (2009) 1.26
Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc (2014) 1.26
Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haematologica (2013) 1.02
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 0.91
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS (2013) 0.86
Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPICOR Study. Thromb Haemost (2014) 0.85
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. AIDS (2012) 0.82
Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci Rep (2015) 0.80
Attitudes of people in the UK with HIV who Are Antiretroviral (ART) Naïve to starting ART at high CD4 counts for potential health benefit or to prevent HIV transmission. PLoS One (2014) 1.17
Finger Prick Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe. PLoS One (2015) 0.84
Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS One (2015) 0.77
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One (2017) 0.75
Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. J Acquir Immune Defic Syndr (2017) 0.75